A Rigorous Interlaboratory Examination of the Need to Confirm Next-Generation Sequencing–Detected Variants with an Orthogonal Method in Clinical Genetic.

Slides:



Advertisements
Similar presentations
Martina I. Lefterova, Peidong Shen, Justin I
Advertisements

Triplet Repeat Primed PCR Simplifies Testing for Huntington Disease
Ane Y. Schmidt, Thomas v. O. Hansen, Lise B
Implementation of a Reliable Next-Generation Sequencing Strategy for Molecular Diagnosis of Dystrophinopathies  Melissa Alame, Delphine Lacourt, Reda.
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Martina I. Lefterova, Peidong Shen, Justin I
Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes
Emily M. Kudalkar, Naif A. M
Haley J. Abel, Hussam Al-Kateb, Catherine E. Cottrell, Andrew J
In Silico Proficiency Testing for Clinical Next-Generation Sequencing
Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-
Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes  Paula Paulo, Pedro.
Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use  Liwen Xu, Xiaoqing You, PingPing.
High-Throughput, Multiplex Genotyping Directly from Blood or Dried Blood Spot without DNA Extraction for the Screening of Multiple G6PD Gene Variants.
Hendrikus J. Dubbink, Peggy N. Atmodimedjo, Ronald van Marion, Niels M
Mark G. Erlander, Xiao-Jun Ma, Nicole C
Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data  David H. Spencer,
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications  Vera Grossmann, Andreas Roller, Hans-Ulrich Klein, Sandra Weissmann,
Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice  Stephan Bartels, Sascha Persing, Britta Hasemeier,
Angela Leo, Andrew M. Walker, Matthew S
Triplet Repeat Primed PCR Simplifies Testing for Huntington Disease
A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia  Ilaria.
Comparison of High-Resolution Melting Analysis, TaqMan Allelic Discrimination Assay, and Sanger Sequencing for Clopidogrel Efficacy Genotyping in Routine.
Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing  Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.
Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis.
Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid  Meenakshi Mehrotra, Rajesh.
Jennifer Kerkhof, Laila C
Getting Things Backwards to Prevent Primer Dimers
Principles and Recommendations for Standardizing the Use of the Next-Generation Sequencing Variant File in Clinical Settings  Ira M. Lubin, Nazneen Aziz,
Eric Samorodnitsky, Jharna Datta, Benjamin M
Somak Roy, Christopher Coldren, Arivarasan Karunamurthy, Nefize S
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes  Mia Y. Platt,
ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing  Colin C. Pritchard, Christina Smith,
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies  Michael J. Kluk, R. Coleman Lindsley,
Comprehensive Diagnostic Testing for Stereocilin
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid  Meenakshi Mehrotra, Rajesh.
Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer  Kazimierz.
Detection of Mutations in Myeloid Malignancies through Paired-Sample Analysis of Microdroplet-PCR Deep Sequencing Data  Donavan T. Cheng, Janice Cheng,
Gene-Expression Variation Within and Among Human Populations
Arpita Ghosh, Fei Zou, Fred A. Wright 
Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test  Bennett O.V. Shum, Ilya.
Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis.
A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients  Stephen.
Jesse L. Montgomery, Nick Rejali, Carl T. Wittwer 
Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants.
Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine  Seokhwi Kim, Charny Park, Yongick Ji, Deok G.
Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next- Generation Sequencing Panel Testing  Wenbo Mu, Hsiao-Mei Lu, Jefferey.
Jennifer A. Hempelmann, Sheena M. Scroggins, Colin C
Bassem A. Bejjani, Lisa G. Shaffer 
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT.
A Variant Detection Pipeline for Inherited Cardiomyopathy–Associated Genes Using Next-Generation Sequencing  Théo G.M. Oliveira, Miguel Mitne-Neto, Louise.
Defining Ploidy-Specific Thresholds in Array Comparative Genomic Hybridization to Improve the Sensitivity of Detection of Single Copy Alterations in Cell.
A Novel Assay for Evaluating Fragile X Locus Repeats
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations  Ian E. Bosdet, T. Roderick.
Dale Muzzey, Shera Kash, Jillian I. Johnson, Laura M
Volume 25, Issue 6, Pages (November 2018)
Evaluation of Second-Generation Sequencing of 19 Dilated Cardiomyopathy Genes for Clinical Applications  Sivakumar Gowrisankar, Jordan P. Lerner-Ellis,
Validation for Clinical Use of, and Initial Clinical Experience with, a Novel Approach to Population-Based Carrier Screening using High-Throughput, Next-Generation.
Katy Hanlon, Lorna W. Harries, Sian Ellard, Claudius E. Rudin 
A Pyrosequencing-Based Assay for the Rapid Detection of the 22q11
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer  Zengliu Su, Dora Dias-Santagata,
Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes  Rajesh R. Singh, Keyur P. Patel, Mark J.
Triplet Repeat Primed PCR (TP PCR) in Molecular Diagnostic Testing for Friedreich Ataxia  Paola Ciotti, Emilio Di Maria, Emilia Bellone, Franco Ajmar,
Development and Validation of a Computational Method for Assessment of Missense Variants in Hypertrophic Cardiomyopathy  Daniel M. Jordan, Adam Kiezun,
Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D
Complex History of Admixture between Modern Humans and Neandertals
The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests  Susan J. Hsiao, Mahesh M. Mansukhani,
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
Presentation transcript:

A Rigorous Interlaboratory Examination of the Need to Confirm Next-Generation Sequencing–Detected Variants with an Orthogonal Method in Clinical Genetic Testing  Stephen E. Lincoln, Rebecca Truty, Chiao-Feng Lin, Justin M. Zook, Joshua Paul, Vincent H. Ramey, Marc Salit, Heidi L. Rehm, Robert L. Nussbaum, Matthew S. Lebo  The Journal of Molecular Diagnostics  Volume 21, Issue 2, Pages 318-329 (March 2019) DOI: 10.1016/j.jmoldx.2018.10.009 Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Study methodology. A: Variant calls can be classified as high-confidence true positive (green) and intermediate-confidence (yellow), using strict thresholds intended to maximize the specificity of the high-confidence set. The intermediate set will contain a mixture of true- and false-positive calls. The study objective was to rigorously determine test-specific criteria that distinguish these two categories. Variant calls that are confidently false positives (red) are typically filtered out using different criteria that emphasize sensitivity. The analogy to a traffic light is illustrative. B: Process for collecting true positive and false positive variant calls for both the clinical and Genome in a Bottle Consortium (GIAB) specimens. Each laboratory's clinically validated next-generation sequencing (NGS) assays, bioinformatics pipelines, and filtering criteria were used for both specimen types. Single-nucleotide variants and indels were collected as shown. Copy number and structural variants were excluded from this study, as were any variants with an unknown confirmation status. Filtering and manual review processes were designed to remove clearly false variant calls but not those considered even potentially true. Manual review was used only with the Lab 1 clinical data. HC, high-confidence. The Journal of Molecular Diagnostics 2019 21, 318-329DOI: (10.1016/j.jmoldx.2018.10.009) Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 Individual quality metric results and statistics. A: Variant call quality scores (QUAL, y axis) for true-positive (TP; blue) and false-positive (FP; red) single-nucleotide variant (SNV) calls in the Lab 1 Genome in a Bottle Consortium (GIAB) data set. The x axis position of each point is randomly assigned. To make density changes visible, a random selection of one-fifth of the TP calls was plotted along with all FPs. In the large data set, some FPs had quite high QUAL scores, demonstrating that this metric is inadequate alone. Corresponding histograms using the full data set without down-sampling are shown in Supplemental Figure S1. B: Random sample of 1000 data points from the same data set plotted in A. All points are displayed. Arrows indicate the two FPs present. One thousand such random samples were generated, and compared with the full data set in A, many would lead to quite different conclusions about the effectiveness of QUAL thresholds. C: Lower bound of the 95% CI on the fraction of FPs flagged (y axis) as a function of the number of FPs used to determine criteria (x axis) assuming that 100% success is observed. The y axis range is 90% to 100%. This calculation used the Jeffreys method (blue), the Wilson score method (red), and the tolerance interval method (gray). All methods produce generally similar results and indicate the validity of any study such as this. For example, using the Jeffreys method, flagging 49 of 49 FPs shows 100% effectiveness, with a CI of 95% to 100%. Many prior studies did not achieve this level of statistical significance (Table 1). Consistent with these CI calculations, small data sets indeed resulted in ineffective criteria (see Results). D: Histogram of per-variant false-discovery rates (FDRs; x axis) for all variants that were observed more than once in the Lab 1 data set, and for which one or more of those calls was an FP. SNVs and insertions and deletions (indels) are combined. An FDR of 100% indicates a fully systematic FP (insofar as we can measure); an FDR of 0% indicates a consistent TP (not shown in this graph). Each unique variant (ie, a genetic alteration that may be present in multiple individuals) is counted once. The y axis range is 0% to 50% of variants. Approximately half of all variants that were FPs were also correctly called as TPs in a different specimen(s) or run(s). Examples of this were observed in both the clinical and the GIAB specimens and included both SNVs and indels. Lab 2 results were similar. Many of these variants have low per-variant FDRs, which usually but not always are correctly called. Repeated TP observations of such a variant provide little information about the accuracy of any following observation of that same variant. This study was underpowered to measure FDRs near 0% or 100%, and many more of these variants may exist than are shown here. The Journal of Molecular Diagnostics 2019 21, 318-329DOI: (10.1016/j.jmoldx.2018.10.009) Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 3 Combining flags. These plots show the cumulative effect (top to bottom) of sequentially combining flags chosen by our algorithm. A and B: Single-nucleotide variants (SNVs) (A) and insertions and deletions (indels; B) in the Lab 1 data set. Red indicates the fraction of all false positives (FPs) captured; blue, the fraction of clinical true positives (TPs); gray, the fraction of FPs captured by two or more flags. The dashed lines illustrate the flags needed to capture 100% of the FPs using at least one flag each. To be conservative, the full set of flags shown here was used (maximizing double coverage) and, in particular, required confirmation of all repeat-associated calls. Note that in the indel analysis, higher QUAL and QD thresholds were required to maximize double coverage than were required to achieve 100% capture of variants by a single flag each. The flags include: DP, read depth, specifically GT_DP; DP/DP, ratio of GT_DP to INFO_DP; SB5 and SB25, strand bias metrics; QUAL, quality score; QD, quality-depth score; ABnorm, allele balance for heterozygotes, normalized to be within 0.0 to 0.5; ABhom, allele balance for homozygotes; HetAlt, heterozygous call for which neither allele is in the GRCh37 reference genome; Repeat, variant call within a homopolymer or short tandem repeat. The Journal of Molecular Diagnostics 2019 21, 318-329DOI: (10.1016/j.jmoldx.2018.10.009) Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions